Phase 2 Osteoporosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a woman who can move around independently, and you are between 45 and 80 years old
- Your periods stopped naturally at least 3 years ago, OR you had surgery to remove your ovaries at least 3 years ago (the surgery must have been done after age 40); if your menopause was caused by surgery, a specific hormone level in your blood (FSH) must be above 40 mIU/mL
- Your body mass index (a measure of weight relative to height) is between 18 and 30
- You have already been formally diagnosed with osteoporosis
- You are able to travel to the hospital on your own to receive injections of the study drug
- You are willing to take part voluntarily and sign a consent form
Who may not be able to join:
- You received a bone-building medication called teriparatide within the last month
- Your osteoporosis is caused by another medical condition, such as Cushing's syndrome, certain bowel or digestive diseases (like Crohn's disease or chronic pancreatitis), rheumatoid arthritis, gout, or multiple myeloma, among others
- You have another condition that affects calcium or bone health, such as parathyroid problems, thyroid problems (unless your condition is well-controlled and stable with normal hormone levels — confirm with trial site), brittle bone disease, softening of the bones, Paget's disease of bone, abnormal calcium levels in the blood, or active kidney stones
- You need to take other osteoporosis medications during the trial, or you regularly take a heart medication called digoxin
- You have serious kidney disease, uncontrolled high blood pressure (160/100 mmHg or above), serious heart problems (such as a recent heart attack, unstable chest pain, or significant heart failure), a certain type of stroke (excluding small vessel strokes), blocked arteries, or cancer, or other serious underlying health conditions
- You have problems with your oesophagus (the tube from your mouth to your stomach) that slow it down, such as reflux disease, narrowing of the oesophagus, or achalasia, or you have difficulty swallowing
- Your blood test results during the screening period show certain abnormalities, including: liver enzyme or liver function levels that are too high, a blood sugar control measure (HbA1c) of 8.5% or above, low white blood cell count, low haemoglobin (a sign of anaemia), low platelet count, or a parathyroid hormone level that is too high (confirm specific values with trial site)
- You test positive for Hepatitis C, syphilis, HIV, or you test positive for Hepatitis B with a high level of the virus in your blood (a low level may still be acceptable if a doctor considers your condition stable — confirm with trial site)
- You had a major operation (not including fracture surgery) in the 6 months before joining, or you are planning a major operation during the study
- You have previously had an organ transplant
- You have a history of drug misuse in the past 6 months
- You are known to be allergic to the study drug
- You have previously had radiation therapy to your bones or skeleton
- You have a mental health condition or any problem affecting your memory or thinking
- The trial doctors decide, for any safety or other reason, that joining would not be appropriate for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13501358705
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) between each intervention group and the control group during the treatment period,about 10weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.